Summary

Report Overview
The Global Post Menopausal Osteoporosis Market reached US$ 9.9 billion in 2023 and is expected to reach US$ 15.2 billion by 2031 growing with a CAGR of 5.4% during the forecast period 2024-2031.
Postmenopausal osteoporosis encompasses the healthcare industry's efforts to prevent, diagnose, and treat osteoporosis in women after menopause. Osteoporosis is a condition marked by diminished bone strength and an elevated risk of fractures, predominantly affecting postmenopausal women. This is primarily due to the hormonal changes that occur during menopause, which lead to a decline in bone density.
Postmenopausal osteoporosis is characterized by a significant decrease in bone mineral density (BMD), defined by the World Health Organization (WHO) as a condition where BMD is 2.5 standard deviations or more below the average for young, healthy women. This reduction in bone density primarily results from the decline in estrogen levels that occurs during menopause, which accelerates the rate of bone loss. As a consequence, postmenopausal women become more susceptible to fractures due to weakened bones.
Market Dynamics: Drivers 
Rising aging population and prevalence of osteoporosis 
Multiple factors drive the demand for the global post-menopausal osteoporosis market. One of the primary factors is the rising aging population and the prevalence of osteoporosis. As the global population ages, the number of postmenopausal women at risk of developing osteoporosis is increasing significantly. According to the World Health Organization (WHO) data in October 2022, the global aging population growing rapidly. In 2020, there were an estimated 1 billion people aged 60 years or older worldwide. By 2030, the global population aged 60 and above will reach 1.4 billion, representing one in six people globally. By 2050, the number of people aged 60 and over will more than double, reaching over 2.1 billion.
Osteoporosis is a prevalent condition globally, characterized by a decrease in bone mass and quality, leading to an increased risk of fractures. The World Health Organization (WHO) has established a diagnostic criterion for osteoporosis based on bone mineral density (BMD) measurements. As per the WHO, osteoporosis is diagnosed when an individual's BMD falls 2.5 standard deviations or more below the average value for young, healthy women. 
According to a BMJ Yale research publication in April 2024, the prevalence of osteoporosis among women is estimated to be around 23.1%, while in men, it is significantly lower at 11.7%. This disparity can be attributed to several factors, including hormonal changes during menopause in women, which lead to accelerated bone loss.
Moreover, key palters in the industry introduce innovative products and approvals that would drive this market growth. For instance, in May 2024, Solarea Bio introduced the beta launch of Bondia, a new daily medical food aimed at helping peri- and postmenopausal women manage bone loss. This initiative is part of the company's broader goal through its consumer health brand, Journa, to raise awareness and provide effective solutions for bone health, particularly for women at heightened risk of osteoporosis due to hormonal changes associated with menopause.
Also, in December 2023, Ambio, Inc., an innovative biotechnology firm focused on developing novel peptide drugs, biosimilars, bioequivalent, and other complex generic medications, announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Forteo (teriparatide injection). This generic product will be marketed and sold by Apotex.
Restraints
Factors such as lack of awareness about postmenopausal osteoporosis, side effects & complications associated with treatment,  and the high treatment costs, are expected to hamper the market.
Market Segment Analysis
The global post-menopausal osteoporosis market is segmented based on drug class, route of administration, distribution channels, and region.
The RANK ligand inhibitors (Denosumab) segment accounted for approximately 52.3% of the global post-menopausal osteoporosis market share.
The RANK ligand inhibitors (Denosumab) segment is expected to hold the largest market share over the forecast period. Denosumab, a fully human monoclonal antibody that targets and inhibits RANK ligand (RANKL), is an important treatment choice in the postmenopausal osteoporosis market. Its distinct mechanism of action and proven effectiveness in lowering fracture risk contribute to its significance as a therapeutic option.
Denosumab selectively targets and binds to RANKL, a protein essential for the development, activation, and survival of osteoclasts, which are the cells that break down bone tissue. By inhibiting RANKL, denosumab significantly reduces osteoclast activity, resulting in decreased bone resorption and increased bone mineral density (BMD). This mechanism helps to fortify bones and decrease the likelihood of fractures, a prevalent complication of osteoporosis, especially in postmenopausal women.
Moreover, key player's strategies such as partnerships & collaborations, and product approvals would drive this segment's growth. For instance, in April 2024, Sandoz announced a settlement with Amgen, resolving all patent disputes related to its denosumab biosimilars, Jubbonti and Wyost. This agreement allows Sandoz to launch these biosimilars in the U.S. market. Jubbonti is specifically approved for several indications, including treatment of postmenopausal women with osteoporosis at high risk for fractures. Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fractures. It is increasing bone mass in women at high risk for fractures who are receiving adjuvant aromatase inhibitor therapy for breast cancer. 
Also, in March 2024, Sandoz announced that the U.S. Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz) as the first and only FDA-approved biosimilars to denosumab, which is sold under the brand names Prolia and Xgeva. Jubbonti is specifically indicated for postmenopausal women with osteoporosis who are at high risk for fractures, as well as for treating glucocorticoid-induced osteoporosis in both men and women at high risk for fractures.
Market Geographical Share
North America accounted for approximately 44.8% of the global post-menopausal osteoporosis market share
North America region is expected to hold the largest market share over the forecast period owing to the high prevalence of osteoporosis, aging population, and investment in research and development drives this market growth.
As per PRB data in January 2024, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of this age group within the overall population is anticipated to rise from 17% to 23%.
Moreover, in this region major number of key players' presence, well-advanced healthcare infrastructure, and innovative product launches & approvals drive market growth. For instance, in November 2023, Teva Pharmaceuticals Inc., the U.S. branch of Teva Pharmaceutical Industries Ltd., announced that it had received approval for a generic version of Forteo (Teriparatide injections) in the United States. Teriparatide injections are used to treat postmenopausal women with osteoporosis who are at a high risk of fractures or who are unable to use alternative osteoporosis therapies. 
Also, in January 2024, The U.S. Food and Drug Administration (FDA) approved Osteoboost, a wearable belt device developed by Bone Health Technologies, as the first non-drug, prescription treatment for postmenopausal women with osteopenia, a precursor to osteoporosis. Osteoboost is designed to deliver calibrated, low-frequency vibrations to the lumbar spine and hips, which stimulates bone growth and helps maintain bone density. The device is worn around the waist during normal daily activities involving standing and walking, with each treatment session lasting 30 minutes.
Market Segmentation
By Drug Class
Bisphosphonates
Risedronate
Alendronate
Zoledronic Acid
Ibandronate
RANK Ligand Inhibitors (Denosumab)
Selective Estrogen Receptor Modulator (SERM) (Raloxifene)
Monoclonal Antibody (Romosozumab)
Parathyroid Hormone Analog
Teriparatide
Abaloparatide
Calcitonin
Strontium
Anti-Sclerostin
Cathepsin K Inhibitors (CatK)
Others
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the post-menopausal osteoporosis market include Sandoz Group AG, Pfizer Inc., Amgen Inc., Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Ambio Inc., and GSK plc.
Key Developments
In July 2024, Romosozumab a humanized monoclonal antibody that inhibits sclerostin, which has received approval from the United States Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women at heightened risk of fractures. This anabolic therapy promotes bone formation while simultaneously reducing bone resorption. Its dual action leads to increased bone mineral density and a decrease in the risk of fractures associated with osteoporosis.
Why Purchase the Report?
To visualize the global post-menopausal osteoporosis market segmentation based on drug class, route of administration, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development. 
Excel data sheet with numerous data points of the post-menopausal osteoporosis market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.
The global post-menopausal osteoporosis market report would provide approximately 62 tables, 61 figures, and 183 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Aging Population and Prevalence of Osteoporosis
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Awareness about Postmenopausal Osteoporosis
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Bisphosphonates *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Risedronate
6.2.4. Alendronate
6.2.5. Zoledronic Acid
6.2.6. Ibandronate
6.3. RANK Ligand Inhibitors (Denosumab)
6.4. Selective Estrogen Receptor Modulator (SERM) (Raloxifene)
6.5. Monoclonal Antibody (Romosozumab)
6.6. Parathyroid Hormone Analog
6.6.1. Teriparatide
6.6.2. Abaloparatide
6.7. Calcitonin
6.8. Strontium
6.9. Anti-Sclerostin
6.10. Cathepsin K Inhibitors (CatK)
6.11. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
7.4. Others
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Hospital Pharmacies *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Sandoz Group AG*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Pfizer Inc
11.3. Amgen Inc.
11.4. Novartis AG
11.5. AbbVie Inc
11.6. Teva Pharmaceutical Industries Ltd.
11.7. Eli Lilly and Company
11.8. Merck & Co., Inc.,
11.9. Ambio Inc.
11.10. GSK plc. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us